Search

Your search keyword '"Cytomegalovirus immunology"' showing total 127 results

Search Constraints

Start Over You searched for: Descriptor "Cytomegalovirus immunology" Remove constraint Descriptor: "Cytomegalovirus immunology" Journal transplantation proceedings Remove constraint Journal: transplantation proceedings
127 results on '"Cytomegalovirus immunology"'

Search Results

1. Comparison of Cytomegalovirus Reactivation in Children After Allogeneic Hematopoietic Cell Transplantation in 2 Transplant Eras.

2. Anti-Donor T-Cell Responses Are Not Necessarily Attenuated During Cytomegalovirus Infection in Kidney Transplant Recipients.

3. Cytomegalovirus Experience in Pediatric Kidney Transplantation in 26 Years' Time.

4. Monitoring of CMV-Specific Cell-Mediated Immunity in Kidney Transplant Recipients With a High Risk of CMV Disease (D+/R-): A Case Series.

5. Cytomegalovirus Infection Monitoring Based on Interferon Gamma Release Assay in Kidney Transplantation.

6. Enzyme-Linked Immunospot Assay as a Complementary Method to Assess and Monitor Cytomegalovirus Infection in Kidney Transplant Recipients on Pre-emptive Antiviral Therapy: A Single-Center Experience.

7. Effect of Cytomegalovirus Infection on Survival of Older Kidney Transplant Patients (D+/R+): Impact of Valganciclovir Prophylaxis Versus Preemptive Therapy.

8. Potential Immunomodulatory Role of Specific Anticytomegalovirus Intravenous Immunoglobulin in Heart Recipients.

9. Clinical Utility of QuantiFERON-Cytomegalovirus Test in Management of Kidney Transplant Recipients.

10. Which CMV viral load threshold should be defined as CMV infection in kidney transplant patients?

11. Risk factors of cytomegalovirus infection after pediatric liver transplantation.

12. Long-term outcomes of pancreas after kidney transplantation in small centers: is it justified?

13. Co-infection and clinical impact of human herpesvirus 5 and 6 in liver transplantation.

14. Monitoring of cytomegalovirus-specific CD8+ T-cell response with major histocompatibility complex pentamers in kidney transplant recipients.

15. Cytomegalovirus seroprevalence among solid organ donors in Hungary: correlations with age, gender, and blood group.

16. Cytomegalovirus, human herpesvirus-6, and human herpesvirus-7 in adult liver transplant recipients: diagnosis based on antigenemia.

17. Evaluation and significance of cytomegalovirus-specific cellular immune response in lung transplant recipients.

18. Monitoring and detection of cytomegalovirus in liver transplant recipients.

19. Quantiferon-CMV test in prediction of cytomegalovirus infection after kidney transplantation.

20. Differences in cytomegalovirus replication quantified using quantitative polymerase chain reaction and antigenemia after allogeneic stem cell transplantation.

21. Prophylactic therapy with valganciclovir in high-risk (cytomegalovirus D+/R-) kidney transplant recipients: a single-center experience.

22. Risk factors for posttransplant lymphoproliferative disorder in pediatric liver transplant recipients with cytomegalovirus antigenemia.

23. The risk factors for cytomegalovirus syndrome and tissue-invasive cytomegalovirus disease in liver transplant recipients who have cytomegalovirus antigenemia.

24. Monitoring cytomegalovirus T-cell immunity in small bowel/multivisceral transplant recipients.

25. Cytomegalovirus-induced adrenal insufficiency in a renal transplant recipient.

26. Is screening for IgG antibody to cytomegalovirus and Epstein-Barr virus infections mandatory in potential renal transplant recipients and donors in Iran?

27. Human cytomegalovirus specific CD8(+) T lymphocytes display interferon-gamma secretion impairment in kidney transplant recipients with pp65 antigenemia.

28. Serological profile of potential solid organ donors in Santa Catarina, Brazil.

29. An animal model of human cytomegalovirus infection.

30. Is gammaglobulin anti-CMV warranted in lung transplantation?

31. Determination of antibodies to Toxoplasma gondii and CMV in renal transplant recipients.

32. Expression of TGF-beta and PDGF-AA antigens and corresponding mRNAs in cytomegalovirus-infected rat kidney allografts.

33. CMV increases TNF-alpha expression in a rat kidney model of chronic rejection.

34. Prophylaxis of cytomegalovirus disease with ganciclovir or anti-CMV immunoglobulin in renal transplant recipients who receive antilymphocytic antibodies as induction therapy.

35. Use of combination cytomegalovirus immune globulin plus ganciclovir for prophylaxis in CMV-seronegative liver transplant recipients of a CMV-seropositive donor organ: a multicenter, open-label study.

36. Effect of mycophenolate mofetil on the Anti-CMV serologic response after renal transplantation.

37. Antiviral drugs can inhibit lymphocyte apoptosis induced by cytomegalovirus antigens.

38. CMV-specific CD8(pos) T lymphocyte differentiation in latent CMV infection.

39. Cyclosporine and anti-CD3 blockade of lymphocyte apoptosis induced by cytomegalovirus antigens.

40. Down regulation of in vivo and in vitro T cell responses post cytomegalovirus immune globulin intravenous (human) administration in sensitized renal transplant candidates.

41. Positive donor cytomegalovirus IgG status as a major risk factor for liver allograft recipient infection.

42. Detection of human cytomegalovirus in renal transplantation: comparison of four diagnostic methods: DNA in sera by polymerase chain reaction (PCR), DNA in leukocyte by PCR, pp65 leukocytic antigenemia, and viremia.

43. Incidence of cytomegalovirus infection in kidney recipients.

44. Increased late rejection in cytomegalovirus-immunoglobulin-M-positive heart transplantation patients.

45. Antiviral antibodies in transplantation.

46. Strong enhancement of HLA class 1 surface expression by incomplete cytomegalovirus particles: analysis by dual-color flow cytometry using saponin.

47. Acyclovir/cytomegalovirus immune globulin combination therapy for CMV prophylaxis in high-risk renal allograft recipients.

48. In vitro induction of endothelial adhesion molecule and MHC antigen expression by cytomegalovirus-activated CD4+ T cells.

49. Incidence of infection and acute rejection after cytomegalovirus immune globulin prophylaxis in renal transplantation.

50. Use of cytomegalovirus (CMV) hyperimmune globulin for prevention of CMV disease in CMV-seropositive lung transplant recipients.

Catalog

Books, media, physical & digital resources